The Journal of Psychology
January 1, 1960
Harold A. Abramson, Anabela P. Rolo, B. Sklarofsky et al.
22 citations
In a small human experiment, participants who developed tolerance to lysergic acid diethylamide also showed cross-tolerance to psilocybin, meaning prior exposure to one drug reduced the effects of the other. The authors suggest that these two hallucinogens act through a common mechanism in the brain to produce psychosis-like states. The study provides early evidence for shared pharmacological pathways between LSD and psilocybin.
Journal of Asthma Research
January 1, 1965
Harold A. Abramson, Anabela P. Rolo
21 citations
Methysergide (Sansert), a derivative of d-lysergic acid used to treat migraine, produces side effects and tolerance, leading researchers to compare its effects with those of LSD-25, psilocybin, and psilocin in non-psychotic test subjects over more than 150 experiments. The experimental environment strongly influences results, sometimes as much as the drug itself. The paper reports on these comparisons, continuing a thirteen-year series of studies with LSD-25 and similar compounds.
The Journal of Psychology
July 1, 1960
Anabela P. Rolo, Leonard W. Krinsky, Liat Goldfarb
10 citations
A single dose of LSD, administered as part of a structured psychotherapy program, was associated with higher rates of sobriety among alcoholics. In a study of 68 alcoholic patients, those who received LSD in addition to standard treatment showed a greater likelihood of remaining abstinent at follow-up compared to those who received only conventional therapy. The authors suggest that the drug may facilitate psychological insight and emotional release, though they caution that the results are preliminary and require further controlled investigation.
The Journal of Psychology
October 1, 1963
Harold A. Abramson, H. H. Gettner, Anabela P. Rolo et al.
6 citations
No Summary
Journal of Asthma Research
January 1, 1979
Harold A. Abramson, H. H. Gettner, P. A. Carone et al.
4 citations
A simplified method for studying the surfacing reaction of goldfish to hallucinogens uses intracranial injection in fish weighing up to three grams. The drugs d-lysergic acid diethylamide (LSD-25), d-2-acetyl lysergic acid diethylamide (ALD-52), 1-methyl d-lysergic acid butanolamide (UML-491), and 5-methoxy dimethyl tryptamine (5-MEO-DMT) were as pharmacologically active as previously noted in fish and in humans. The relationship of these drugs to their anti-serotonin activity is of particular interest to allergists because the congeners and derivatives of LSD block the action of serotonin on smooth muscle.